The purpose of the study is to assess how well these extracts identify allergic versus non‑allergic individuals by measuring the test’s sensitivity and specificity. Participants will attend a clinic visit where a tiny amount of each solution is placed on the forearm and gently pricked into the skin using a skin prick test method; a control drop without allergen is also used. After a few minutes the size of any raised, red bump (called a wheal) is measured, and the results are compared with the person’s medical history to determine accuracy. The study follows participants for a short period after the test to complete the assessments.

The purpose of the study is to evaluate whether the new scan can improve the detection and assessment of tumor lesions at the time of first diagnosis, during treatment, and if the disease returns. Participants will receive the injection, then lie on a scanning table while the machine takes images; this will be done at several visits that match the usual points when doctors check the disease. The images are read by doctors to see how well the new substance works compared with the standard one, and the overall experience of the children and their families is also recorded.

The purpose of the study is to determine whether the new [68Ga]FAPI-46 scan can identify additional metastatic lesions when the standard scan does not show clear results. After the initial standard scan, participants undergo the experimental scan, and if any suspicious spots are seen, a small tissue sample may be taken for histology—the process of examining cells under a microscope—to confirm whether the spots are cancer. The imaging reports also note the SUVmax value, a number that reflects how strongly the tracer accumulates in a lesion.

Throughout the study, the imaging results are reviewed by specialists, any needed biopsies are performed, and the findings from both scans are compared to see which method detects more disease spread. The entire process takes place over a short series of visits, and no additional treatment is given beyond the imaging procedures.

The purpose of the study is to determine how well this imaging test can identify the original location of the cancer and any spread, as well as to assess its ability to detect cancer that may return after treatment. Participants will receive an injection of the radioactive substance, wait a short period for it to circulate, and then undergo the scan. A follow‑up scan may be performed later to see any changes. “Staging” means finding the size and spread of cancer at diagnosis, while “restaging” refers to checking again after therapy. “Sensitivity” describes the test’s ability to correctly find cancer when it is present, “specificity” means correctly showing no cancer when it is absent, “predictive values” indicate how likely the results are to be correct, and “accuracy” reflects the overall correctness of the test.

The scan results will be compared with the tissue analysis that doctors perform after surgery to see if they match. The study will also look at whether the imaging changes the doctor’s view of the cancer stage, leads to different treatment choices, or reveals unexpected findings. Throughout the study, safety checks will be carried out to ensure that the injection and scanning procedure are well tolerated.

The purpose of the study is to identify potential pathways in the body that lead to fibrosis in patients treated with filgotinib and to monitor these changes using FAPi-PET/CT imaging. Participants in the study will receive the treatment and undergo imaging scans to observe any changes in their condition. The study will last for several months, with participants being monitored at different stages to assess the effects of the treatment and the progression of fibrosis.

Throughout the study, researchers will analyze changes in gene and protein expression in the participants’ tissues to better understand how the treatment affects the body. This information will help in identifying specific pathways that may be involved in the development of fibrosis in ulcerative colitis. The findings from this study could provide valuable insights into new ways to manage and treat this condition in the future.

The purpose of the study is to determine which of these treatments leads to a shorter stay in the hospital for patients whose infection does not improve with the initial antibiotics and drainage. After a patient is enrolled, they receive either the surgical procedure or the medication combination, stay in the hospital while doctors watch for improvement, and are then followed for about a month to see how quickly they can leave the hospital and return to normal activities.

During the follow‑up, information is collected on how long the chest tube remains, any need for additional procedures, pain levels, ability to perform daily tasks, and overall quality of life. The study also looks at the costs related to health care and any loss of work time, helping to understand the broader impact of each treatment option.

The purpose of the study is to estimate how often the PET scan shows a positive result in these patients. After the injection, the scan is performed and the images are read by three experts who look for a spot of increased uptake, described as a “positive” scan. Participants are then followed for about a year to see whether the scan results lead to surgery or radiation treatment, and to observe any changes in hormone levels. The study also records technical details of the scan, such as the amount of signal measured by SUVmax, SUVmean and SUVpeak, to better understand how the test works in different tumor types.

The purpose of the study is to evaluate how well the PSMA PET/CT scan can detect cancer recurrence one year after HIFU treatment. Participants will have the imaging tests at the one‑year follow‑up, and any suspicious areas will be checked with a biopsy, which serves as the reference standard. The results will be collected to determine the accuracy of the imaging methods.

The purpose of the study is to find out whether this imaging test can accurately show how severe the heart involvement is. After the injection, a short‑lasting scan using PET technology will be done, which creates pictures of the heart by detecting the injected substance. Depending on the equipment available, the scan may be combined with either a CT scan (a type of X‑ray picture) or an MRI scan (a magnetic scan that shows detailed pictures of the heart).

Participants will be monitored for any immediate reactions right after the injection and then again a few minutes later. The imaging session lasts about one hour, during which the heart is photographed from different angles. All information gathered will be used only to understand how well the new imaging method works for this disease.

Participants will receive a single injection of the imaging agent, followed by a series of imaging sessions that combine PET and CT scans to look at the transplanted kidney, nearby lymph nodes, spleen, liver and bone marrow. A small blood sample will also be taken to measure immune cells using a laboratory technique called flow cytometry. The study lasts for a short period of time after the injection, during which the imaging and blood tests are performed to assess the distribution of the agent and the activity of immune cells.

During the scan, a short‑acting medicine is given through an IV to make the heart work a little harder, allowing doctors to see how the blood vessels respond. The medicines used are Adenosine and regadenoson, both of which safely cause a temporary rise in heart workload. A small amount of a harmless radioactive substance, O15-water, is also injected so the scanner can create detailed pictures of blood flow. The amount of blood moving through the heart muscle is expressed as MBF, which helps identify areas that may not be getting enough oxygen.

The purpose of the study is to find specific numbers that can predict the chance of future major heart problems, known as MACE. Participants undergo the PET scan with the stress medicines, then are followed for several years while information about any heart attacks, deaths, or related events is recorded. This follow‑up helps determine which scan results are linked to higher or lower risk.

The study is for people with stomach cancer that may still be treated with the goal of cure. After the standard tests already used for staging, the participant receives the 68Ga-FAPI-46 injection and then has a PET-CT scan. The doctors then compare the new scan with the usual test results to see whether the understanding of how far the cancer has spread changes in a helpful way. This includes checking the TNM classification, which is a common way to describe the size of the tumor, whether nearby lymph nodes are involved, and whether the cancer has spread to other parts of the body.

The study also looks at whether the scan changes the planned treatment, such as surgery, chemotherapy, or radiotherapy. It is focused on how well the scan can help with the first staging of the disease, including the usual surgical look inside the abdomen when that is part of care. The study uses several forms of the same product for making the radioactive substance, including GalliaPharm and Galliad, but the imaging substance used in the scan is 68Ga-FAPI-46.

The specific substance being tested is iomeprol, which is administered through an intravenous injection, meaning it is delivered directly into a vein. During the trial, participants will undergo imaging using both the standard dose and half the dose of the contrast. The study will evaluate how well the images show blood vessels and organs to ensure that using a smaller amount of the substance still provides clear and useful information for monitoring the disease.

The study involves applying these different solutions to the skin to observe the physical response. This response is measured by looking at the wheal, which is a small, raised, itchy bump on the skin that appears during an allergic reaction. By measuring the size of these bumps, the relationship between the amount of pollen extract and the body’s reaction can be determined. The process helps to ensure that the pollen extracts used in medical settings are consistent and reliable.

During the study, participants will be assigned to one of the two treatment groups to receive either Clensia or CitraFleet. The goal is to determine which preparation better allows the doctor to find adenomas, which are small growths on the lining of the colon that can potentially become cancer, and polyps, which are other types of growths found in the intestine. The study will also look at how well the bowel is cleaned and how much gas or bubbles are present during the procedure, as these can make it harder for the doctor to see clearly.

The process involves taking the assigned liquid before the medical procedure and then undergoing the colonoscopy. Information will be collected regarding how easy or pleasant the liquid was to drink and any side effects experienced, such as nausea, vomiting, or abdominal pain. The study evaluates how successfully the doctor can reach the end of the large intestine, known as the cecum, and how much time is needed to complete the examination.

During the study, participants will receive an intravenous injection, meaning the substance is delivered directly into a vein. After the injection, the imaging process will be performed to look for signs of cancer in the abdominal area. The effectiveness of the GEH300079 (68Ga) injection will be compared to standard imaging methods currently used in medical practice to see if this new method provides more accurate information about the presence and location of cancer cells.

The purpose of the study is to check how well 68Ga-Pentixafor PET/CT can detect cardiac sarcoidosis. The results from this new scan will be compared to another scan called 18F-FDG PET/CT, which is already used in regular medical practice to look for this condition. The study will involve patients who have sarcoidosis in other parts of their body and who are suspected of having or already have cardiac sarcoidosis. These patients will receive the 68Ga-Pentixafor injection and undergo the PET/CT scan in addition to their regular 18F-FDG scan.

During the study, doctors will look at the scan images to see if and where the 68Ga-Pentixafor is taken up in the heart muscle. They will measure how much of the substance appears in different areas and describe the pattern of uptake, whether it appears in small spots or spread throughout the heart. The images will be examined by experienced doctors who will compare their findings. The study will also check if the substance shows up in other organs that might be affected by sarcoidosis and will look at how the substance moves through the body over time.

During the study, patients will undergo PSMA PET/CT scans, which are special imaging tests that combine two types of scans to find and measure prostate cancer in the body. These scans will be done before starting the treatment and again after taking darolutamide to compare the results. The study will look at whether the number of cancer deposits increases, whether existing cancer spots show higher levels of the PSMA protein, or whether the cancer spots become larger or more visible after treatment with darolutamide. This effect, where the visibility of cancer temporarily increases after starting certain hormone-blocking treatments, is sometimes called a flare phenomenon.

Patients participating in this study will have already received previous treatment for their prostate cancer, either surgery to remove the prostate or radiation therapy, and their scans will show between one and five areas where the cancer has spread to bones or lymph nodes. The study will also collect information about any side effects that occur and how patients feel during the treatment by using quality of life questionnaires. The measurements taken during the scans will include the number of cancer spots, their size, their location in the body, and a measurement called SUVmax which indicates how much the PSMA protein is present in each spot.

The purpose of this study is to check if gadopiclenol works well for finding and tracking perianal fistulas when used during magnetic resonance imaging, which is also called MRI, a type of scan that uses magnets and radio waves to create detailed pictures of the inside of the body. Participants will receive both contrast agents at different times during the study, with each one being given through a vein before an MRI scan is performed. The study follows a crossover design, which means that each person will have scans with both contrast agents so that doctors can compare how well each one works in showing the fistula tract, which is the path or tunnel of the abnormal connection.

During the study, doctors will look at the MRI images to see how clearly they can identify the perianal fistula when each contrast agent is used. They will also measure technical aspects of the images, such as how much difference there is between the fistula and the healthy tissue around it, and how much the contrast agent brightens the fistula area compared to before it was given. This information will help determine if gadopiclenol is as effective as gadobutrol for this specific use in people with Crohn’s disease and perianal fistulas.

The purpose of this study is to gather information that will help plan a larger study in the future. Researchers want to compare how well the new imaging substance 68Ga-FAPI-46 works compared to the standard method that uses fludeoxyglucose (18F) and brain MRI for finding cancer that has spread to other parts of the body in patients who have been newly diagnosed with non-small cell lung cancer. The study will look at how many cancer spots are found with each method and where these spots are located in the body.

During the study, patients will receive scans with both imaging substances. They will first have or will have already had a scan with fludeoxyglucose (18F) as part of their regular care. Within three weeks, they will also receive a scan using 68Ga-FAPI-46. If a brain MRI has not already been done, patients will also undergo this scan. Doctors will then compare the results from both types of scans to see if the new substance finds cancer spots that the standard method might miss, or if the standard method finds spots that the new substance does not detect.

The purpose of this study is to collect detailed information about lung structure and function before and after radiotherapy treatment. By comparing images taken before treatment starts with images taken after treatment is completed, researchers want to see what changes happen in the lungs as a result of the radiotherapy. These changes will be looked at by examining ventilation maps, which are special images that show how air moves through different parts of the lungs. The study aims to identify areas where the lung function may have improved or worsened due to the radiation treatment.

During the study, participants will undergo scanning sessions where they will breathe in the xenon and oxygen gas mixture while lying in the CT scanner. The scans will capture images of the lungs while the gas is present, allowing doctors to see which areas of the lungs are receiving good airflow and which areas may not be working as well. Participants will need to hold their breath for short periods of about three seconds during the scanning. The study will involve scans done before the radiotherapy begins and again after the radiotherapy treatment has finished, so that doctors can measure and compare any changes that have occurred in lung function and tissue structure.

The purpose of the study is to compare how much of the imaging substance is taken up by the tissues around the eyes in patients who have active disease versus those who have inactive disease. Active disease means the condition is currently causing noticeable symptoms and changes, while inactive disease means the condition has been stable and quiet for at least six months. The study will involve patients receiving an injection of the imaging substance and then undergoing a PET scan combined with an MRI scan. A PET scan is a type of imaging that shows how tissues and organs are functioning by detecting the injected substance, while an MRI scan uses magnetic fields to create detailed pictures of the body’s internal structures.

During the study, researchers will examine the scan images to see how much of the substance accumulates in the eye tissues of patients with active disease compared to those with inactive disease. They will also look at how the scan results relate to other measurements such as swelling seen on the MRI, the symptoms patients are experiencing, and laboratory test results. This information may help doctors better understand and assess the activity level of the disease in future patients.

The purpose of the study is to see whether imaging with [68Ga]Ga-FAPI can help doctors see changes in the blood vessels of the lungs in people with pulmonary arterial hypertension without needing invasive procedures. The study will look at whether this imaging method can show these changes and whether the changes can be seen after treatment with sotatercept. The study will also look at how the imaging results relate to other measurements of how well the heart and lungs are working, such as exercise ability and blood test results.

People in the study will have imaging scans at the beginning and then again after receiving treatment with sotatercept. The imaging will include scans using both [68Ga]Ga-FAPI and [68Ga]Ga-MAA to look at different aspects of the blood vessels and blood flow in the lungs. The study will also measure how well the right side of the heart is working and compare the imaging results with other tests that are commonly used to check pulmonary arterial hypertension, including heart function tests, walking tests, and blood tests. The entire study is expected to last until March 2027.

During the study, participants will receive a single injection of the study medication. The medication works by attaching to a specific protein called Carbonic Anhydrase IX that is often found on the surface of tumors related to this condition. After the injection, special imaging scans will be performed to see if the medication can help detect tumors in the body. This type of imaging is called CAIX-PET, which uses the study medication to create images that may show where tumors are located.

The study will look at how well this imaging method can find tumors in people with Von-Hippel Lindau disease and in people with certain types of tumors that can occur without the genetic condition. The study will also check the safety of using this imaging approach. Participants will be followed for a period of time after receiving the injection to monitor for any side effects and to complete the imaging procedures.

The study involves giving patients an injection of gadopiclenol before their scheduled MRI scan. This contrast agent helps make certain areas of the body more visible during the scan. The examination will take place before planned breast cancer surgery. The dose of gadopiclenol used in the study is 0.5 millimoles per milliliter, given as a single injection.

During the study, doctors will compare the detailed images from the MRI scan with the results from examining the breast tissue after surgery. They will look at various features of the cancer seen on the MRI images, such as size and appearance, and compare these with the actual characteristics of the tumor found during laboratory examination of the surgically removed tissue. This will help determine how accurate the contrast-enhanced MRI is in showing the details of breast cancer.

The study aims to determine if cardiac magnetic resonance imaging (CMR) can detect early heart damage in patients receiving anthracycline treatment. During CMR scans, a special substance called contrast agent is used to make certain parts of the heart more visible in the images.

Throughout the treatment period, which may last up to 8 months, participants will undergo several CMR scans and blood tests. The study will look for changes in heart tissue and measure certain substances in the blood that might indicate heart damage. Participants will also receive regular heart ultrasound tests called echocardiograms to monitor their heart function during treatment.

During the study, healthy individuals will receive a single dose of HarMono-T through an intravenous injection. Four different dose levels will be tested. The contrast agent consists of tiny bubbles that improve the visibility of kidney structures during ultrasound imaging. After receiving the injection, participants will undergo kidney ultrasound examinations to assess how well the contrast agent works.

The study will monitor participants’ health through various medical checks, including blood tests and heart monitoring. A final ultrasound examination will be performed 30 minutes after receiving the contrast agent to confirm that it has completely cleared from the body. Participants will be followed for approximately one week after receiving the injection to check for any potential side effects.

The purpose of the study is to determine whether using this special contrast-enhanced imaging technique can provide better information about cancer spread to lymph nodes compared to standard imaging methods. This is important both before and after patients receive initial cancer treatment with chemotherapy and radiation therapy.

During the study, participants will receive a single dose of Ferrotran through an infusion into their vein. The amount given depends on the person’s weight. They will then undergo MRI scanning to create detailed images of the lymph nodes. The imaging procedure will be performed twice – once before starting cancer treatment and once after completing it. The total duration of participation in the imaging part of the study is 2 days.

The purpose of this research is to compare two different approaches to planning radiation treatment. One approach uses functional lung imaging that shows blood flow patterns in the lungs, while the other uses traditional anatomical planning. The study aims to determine if using the blood flow imaging method results in fewer breathing problems or lung damage after radiation treatment.

During the study, participants will receive their prescribed radiation therapy and will have follow-up visits over one year to monitor their progress. The imaging agent will be used to create detailed pictures of their lungs before treatment and again three months after treatment. Doctors will check for any breathing difficulties or lung-related side effects throughout the study period. The maximum amount of the imaging agent used will be 200 MBq per scan, with a total of 400 MBq over two days.

The study involves using a skin-prick test solution containing different concentrations of Lepidoglyphus destructor extract. During the test, small amounts of the solution are placed on the skin through tiny pricks. The test also includes a histamine dihydrochloride solution as a positive control and a sodium chloride solution (salt water) as a negative control to ensure accurate results.

The testing procedure involves measuring the skin’s reaction to different strengths of the extract. The skin reaction appears as a small raised area called a wheal, which is measured to determine how well the extract works in identifying allergies. The study takes place over a single day for each participant, with careful monitoring for any allergic reactions during the testing period.

The study involves using various concentrations of the allergen extract through intraepidermal application, which means the solution is applied just under the surface of the skin. During the testing, histamine dihydrochloride will be used as a positive control substance, and sodium chloride (salt water) as a negative control to ensure accurate results. The skin’s reaction to these substances will be measured and compared.

The purpose of this research is to establish the correct concentration of the allergen extract that produces a skin reaction comparable to a standard allergic response. This will help determine the proper strength of the extract for future use in allergy testing. The study will also monitor any unwanted reactions that might occur during the testing process to ensure the safety of the procedure.

The purpose of this study is to investigate changes in the brain’s serotonin system during the early stages of Parkinson’s disease. The research specifically looks at people who carry a particular genetic change in the SNCA gene, which is associated with Parkinson’s disease. The study will compare these individuals with healthy people who do not have this genetic change.

During the study, participants will receive the imaging substances through an intravenous injection. They will undergo brain scanning procedures that include MRI (Magnetic Resonance Imaging) and other specialized imaging tests. The study will examine how these substances bind to specific areas in the brain and what this reveals about the early stages of the disease.

The study focuses on patients whose melanoma cannot be surgically removed or has spread to other parts of the body. Patients with brain metastases (cancer that has spread to the brain) may participate if these metastases are asymptomatic or have been treated. The purpose is to determine if the IOpener-melanoma test can accurately predict which patients will benefit from combination therapy or monotherapy with immune checkpoint inhibitors.

During the study, participants will receive treatment based on their IOpener-melanoma test results. The study will track how patients respond to treatment, including how long they live without their disease getting worse, overall survival, and quality of life measures.

Contrast-enhanced ultrasound is a technique where special contrast agents like Sonazoid™ are injected into the bloodstream to improve the visibility of internal organs and blood vessels during an ultrasound examination. During the study, participants will receive Sonazoid™ intravenously (through a vein) while undergoing ultrasound imaging of their liver. The images will be taken during different phases including the vascular phase (when the contrast agent is flowing through blood vessels) and the Kupffer phase (when the contrast agent is taken up by special cells in the liver).

The study will compare the images obtained with Sonazoid™ to those from regular ultrasound without contrast, as well as to the participant’s baseline diagnosis established through other imaging methods like contrast-enhanced computed tomography (CECT) or contrast-enhanced magnetic resonance imaging (CEMRI). Participants will be monitored for safety for 72 hours after receiving Sonazoid™.

The purpose of the study is to determine if using the IV contrast CT is better at diagnosing the cause of acute abdomen in these patients compared to a CT scan without contrast. Participants will be randomly assigned to receive either the contrast-enhanced CT or the non-contrast CT. The study will monitor participants for up to 90 days to observe outcomes such as overall survival, the need for kidney support treatments, and any changes in kidney function.

Throughout the study, researchers will also look at other factors, such as the severity of any acute kidney injury (AKI)</b) that might occur, any organ dysfunction, and the number of days participants spend out of the hospital. The study aims to provide valuable information on the best imaging approach for patients with acute abdomen and impaired kidney function, potentially improving diagnosis and treatment strategies in the future.